2025 NRG Oncology Summer Meeting

2025 NRG Oncology Summer Meeting is organized by NRG Oncology and will be held from Jul 24 - 26, 2025 at Marriott Marquis Washington, DC, Washington, Dist of Col, United States of America.

Why Attend?
NRG Oncology's meetings are where meaningful collaborations ignite innovative cancer research.

Team science isn't a passive experience behind a screen - it's a handshake, a shared idea, and the conversations that happen beyond the agenda. These meetings bring people together to do the real work: build relationships, exchange expertise, and shape the future of cancer care.

This new era of NRG meetings blends virtual accessibility with the power of in-person connection. All disease-specific committees will meet face-to-face, drawing our internationally recognized investigators and leaders into one dynamic space to advance science - both formally and informally.

With a research agenda spanning prevention, detection, treatment, and quality of life, we bring together diverse voices from across disciplines and specialties. Attendees will find opportunities to contribute, collaborate, and move research forward. Together, we'll review progress, share discoveries, and plan next steps - all in pursuit of our shared mission: improving the lives of patients with cancer, and their families.

NRG Oncology will offer a full program that includes scientific sessions, engaged educational session for early-career investigators, and opportunities for networking events. We are excited to offer an expanded Summer Symposium.

NRG Oncology Summer 2025 Symposium - Antibody Drug Conjugates: Selection, Sequencing and Future Strategies in Solid Tumors: Thursday, July 24, 2025 - 8 - 12 pm Eastern
Program Description:
The use of antibody-drug conjugate (ADC) therapy has ushered in a new era in oncology, significantly transforming the management of a range of solid tumor malignancies. This session offers a valuable opportunity to explore the expanding role of ADCs in the treatment of ovarian, cervical, endometrial, breast, lung, genitourinary and gastrointestinal cancers, highlighting their impact on clinical practice and patient outcomes. The latest practice-changing clinical trial results will be provided and reviewed in context with challenging clinical practice scenarios in cancer patients treated with ADC. Expert led discussions will provide evidence-based perspectives regarding important clinically relevant topics in drug selection, biomarkers, sequencing, and toxicity management. We will also review the future landscape of care and current as well as upcoming clinical trials. This timely and clinically relevant session aims to equip attendees with actionable knowledge that can be immediately applied in oncology practice. Interactive case vignettes will offer practical guidance on patient selection, therapeutic strategies, and the management of adverse effects associated with ADCs. Additionally, ongoing and planned pivotal clinical trials will be discussed and the future of clinical trial design in the era of current ADC and novel future therapies will be explored.

Learning Objectives:
Following this activity, participants will be better able to:

• Explain the development and mechanism of action of antibody-drug conjugates (ADCs) and identify mechanisms of resistance.
• Discuss the clinical application of ADCs in the treatment of gynecologic, breast, lung, genitourinary (GU), and gastrointestinal (GI) malignancies.
• Recognize and Manage adverse events associated with ADC therapy.